HCPCS Level II · Miscellaneous services (temporary codes)
Q5170Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About Q5170
Q5170 is an HCPCS Level II code in the Q series (miscellaneous services (temporary codes)), describing injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg.
It was added to HCPCS effective 07/01/2026.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, aflibercept-boav, 1 mg
- Date added
- 07/01/2026
- Action effective
- 07/01/2026
- BETOS
- O1E
Related Q51xx codes
- Q5100Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
- Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
- Q5113Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Common questions about Q5170
Is HCPCS Q5170 still valid?
- Yes. Q5170 is active in the CMS October 2026 HCPCS file.
Does Medicare cover Q5170?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.